project id: TCGA-PRAD; case submitter id: TCGA-VP-A87H; selected normal wgs: true; source center: 23; state: released; a260 a280 ratio: 1.95; normal tumor genotype snp match: Yes; ribosomal rna 28s 16s ratio: 1.38; rna integrity number: 8.7; age at index: 76; days to birth: -28060; ethnicity: not reported; gender: male; race: white; vital status: Alive; year of birth: 1933; age at diagnosis: 28060; ajcc clinical m: M0; ajcc clinical t: T2; ajcc pathologic n: N0; ajcc pathologic t: T3b; classification of tumor: not reported; days to diagnosis: 0; days to last follow up: 663.0; icd 10 code: C61; last known disease status: not reported; morphology: 8140/3; primary diagnosis: Adenocarcinoma, NOS; primary gleason grade: Pattern 4; prior malignancy: no; prior treatment: No; progression or recurrence: not reported; secondary gleason grade: Pattern 5; site of resection or biopsy: Prostate gland; synchronous malignancy: No; tissue or organ of origin: Prostate gland; tumor grade: Not Reported; year of diagnosis: 2009; treatment or therapy: no; alcohol history: Not Reported; is ffpe: false; composition: Not Reported; days to collection: 1714; days to sample procurement: 0; initial weight: 50.0; portion submitter id: TCGA-VP-A87H-01A-11; percent lymphocyte infiltration: 0.0; percent monocyte infiltration: 0.0; percent necrosis: 0.0; percent neutrophil infiltration: 0.0; percent normal cells: 40.0; percent stromal cells: 0.0; percent tumor cells: 60.0; percent tumor nuclei: 70.0;